Analysts estimate that Vir Biotechnology will report an earnings per share (EPS) of $-0.84. Vir Biotechnology bulls will hope to hear the company announce they've not only beaten that estimate, but ...

Net Cash Consumed: $75.6 million in Q1 2025. Vir Biotechnology Inc (NASDAQ:VIR) successfully initiated the ECLIPSE Phase III registrational program for hepatitis delta virus, marking a significant ...

Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. "We successfully dosed the first patient in our ECLIPSE Phase 3 registrational program for hepatitis delta, a devastating disease with no ...

Vir Biotechnology (NASDAQ:VIR) is set to give its latest quarterly earnings report on Wednesday, 2025-05-07. Here's what investors need to know before the announcement. Analysts estimate that Vir ...